Profile
Our research pioneers innovative strategies to address chronic human diseases by balancing immune tolerance and inflammation, primarily regulated by gut microbiota. We aim to understand the crucial role of metabolites in immune system communication and the influence of energy pathways on inflammation modulation. Our central objective is to explore the intricate connection between the gut microbiome and immune system development in various organs, especially the colon, spleen, and brain, across different age groups. We seek to unravel how disruptions in the gut microbiome, clinical disease manifestations, and changes in brain-centric T-cell framework contribute to inflammation-associated cognitive disorders. Our focus includes deciphering how microbiota produce specific metabolites crucial for T-cell balance and investigating the role of the beta-catenin-mTOR pathway in exacerbating infections by affecting T-cell differentiation. Additionally, we will study the complex relationships between microbiota, and developmental anomalies in offspring brains affected by congenital infection-induced cognitive disorders. Through this, we aim to identify potential intervention strategies to mitigate these processes' consequences and pave the way for therapeutic and preventive measures to reduce disease burden in humanity.
Current Focus Areas
Our research investigates the synergy of microbial ecology and metabolomics on organ-specific immune dynamics during infectious diseases. We explore the gut microbiome's connection to immune system development in the colon, spleen, and brain across age groups. We aim to understand how disruptions lead to inflammation-related cognitive disorders.
Selected Publications
Ahuja, R.,* Kaur, A., Kumari, G., Kumar, A., Kumar, S., Roy, A. K., & Majumdar, T.* (2023). Enhanced expression and solubility of main protease (Mpro) of SARS-CoV-2 from E. coli. Protein expression and purification, 211, 106337.
Mani, S., Kaur, A., Jakhar, K., Kumari, G., Sonar, S., Kumar, A., Das, S., Kumar, S., Kumar, V., Kundu, R., Pandey, A. K., Singh, U. P., & Majumdar, T.* (2023). Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections. International journal of biological macromolecules, 245, 125444.
Dwivedy, A., Mariadasse, R., Ahmad, M., Chakraborty, S., Kar, D., Tiwari, S., Bhattacharyya, S., Sonar, S., Mani, S., Tailor, P., Majumdar, T.,* Jeyakanthan, J.,* & Biswal, B. K.* (2021). Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2. PLoS computational biology, 17(9), e1009384.
Majumdar, T.,* Sharma, S., Kumar, M., Hussain, M. A., Chauhan, N., Kalia, I., Sahu, A. K., Rana, V. S., Bharti, R., Haldar, A. K., Singh, A. P., & Mazumder, S. (2019). Tryptophan-kynurenine pathway attenuates β-catenin-dependent pro-parasitic role of STING-TICAM2-IRF3-IDO1 signalosome in Toxoplasma gondii infection. Cell Death & Disease, 10(3), 161.
Goswami, R., Majumdar, T., Dhar, J., Chattopadhyay, S., Bandyopadhyay, S. K., Verbovetskaya, V., Sen, G. C., & Barik, S. (2013). Viral degradasome hijacks mitochondria to suppress innate immunity. Cell research, 23(8), 1025–1042. (Joint 1st Author) * Corresponding author